Background: Poland syndrome is a rare congenital condition characterized by unilateral breast deformity. Autologous fat transplantation has emerged as the preferred treatment due to its minimal invasiveness, rapid recovery, absence of rejection reactions, and potential for multiple surgeries to enhance postoperative outcomes. Previous animal studies have shown that botulinum toxin significantly improves fat retention rates following fat transplantation. Therefore, we aim to initiate a clinical study to investigate the effects of botulinum toxin on human fat transplantation.
Objective: This prospective comparative clinical study aims to evaluate the impact of combining botulinum toxin with autologous fat grafting on fat retention rates in patients with Poland syndrome.
Method: From October 2017 to December 2023, we enrolled 20 Poland syndrome patients, assigning them to an experimental group receiving fat and botulinum toxin for breast augmentation and a control group undergoing standard autologous fat grafting. Postoperative fat retention rates were compared, and outcomes were assessed using the Breast-Q score, alongside baseline patient data.
Results: There were no significant differences in baseline data between the two groups. At 3 and 6 months postoperatively, the fat retention rate in the experimental group was significantly higher than that in the control group. Regarding Breast-Q scores, the control group exhibited significantly lower scores in the Satisfaction with breast domain than the experimental group, with no notable differences in other domains.
Conclusion: The injection of a mixture of fat and botulinum toxin significantly enhances fat retention rates in patients with isolated breast deformities associated with Poland syndrome.
Trial Registration: This study has been registered with the China Clinical Trial Center (ChiCTR2100054878).
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11826372 | PMC |
http://dx.doi.org/10.1111/jocd.70070 | DOI Listing |
Cells
February 2025
Department of Molecular and Cellular Biology, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211a, 50-556 Wroclaw, Poland.
Several molecular pathways are likely involved in the regulation of cancer stem cells (CSCs) via Ras-associated C3 botulinum toxin substrate 2, RAC2, and pituitary tumor-transforming gene 1 product, PTTG1, given their roles in cellular signaling, survival, proliferation, and metastasis. RAC2 is a member of the Rho GTPase family and plays a crucial role in actin cytoskeleton dynamics, reactive oxygen species production, and cell migration, contributing to epithelial-mesenchymal transition (EMT), immune evasion, and therapy resistance. PTTG1, also known as human securin, regulates key processes such as cell cycle progression, apoptosis suppression, and EMT, promoting metastasis and enhancing cancer cell survival.
View Article and Find Full Text PDFJ Cosmet Dermatol
March 2025
Department of Facial Plastic & Cranio-Maxillo-Facial Surgery, Fakih Hospital, Khaizaran, Lebanon.
Botulinum neurotoxin (BoNT) is a highly lethal toxin produced by the anaerobic bacterium Clostridium botulinum, which leads to nerve paralysis following poisoning. At present, there is no specific drug officially approved. Antibodies, particularly single-domain antibodies, represent safe and effective candidates for specific drugs against BoNT.
View Article and Find Full Text PDFJ Pharm Bioallied Sci
December 2024
Department of Clinical Dental Sciences, Ajman University, Ajman, United Arab Emirates.
Dentists' role in facial esthetics is growing, with advancements in cosmetic procedures, such as Botox and dermal fillers. Understanding the range of practitioners and their professional backgrounds is crucial for addressing risks. Data collection and analysis was done to retrieve scholarly papers using databases, such as PubMed and advanced Google search, and analyze.
View Article and Find Full Text PDFMayo Clin Proc Innov Qual Outcomes
April 2025
Department of Physical Medicine and Rehabilitation, Michigan Medicine, University of Michigan, Ann Arbor, MI.
Objective: To examine the most common patterns of pain and symptom management strategies among adults living with cerebral palsy (CP), and to determine if there are differences by pain phenotype or co-occurring neurodevelopmental disorders.
Patients And Methods: Federally insured beneficiaries were included if they had an ICD-9-CM/ICD-10-CM diagnosis code for CP (N=41,595). The study took place from January 10, 2024, to December 15, 2024.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!